The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Dual Cyclooxygenase/5-Lipoxygenase Inhibitor Licofelone Attenuates P-Glycoprotein-Mediated Drug Resistance in the Injured Spinal Cord
Abstract
There are currently no proven effective treatments that can improve recovery of function in spinal cord injury (SCI) patients. Many therapeutic compounds have shown promise in pre-clinical studies, but clinical trials have been largely unsuccessful. P-glycoprotein (Pgp, Abcb1b) is a drug efflux transporter of the blood-spinal cord barrier that limits spinal cord penetration of blood-borne xenobiotics. Pathological Pgp upregulation in diseases such as cancer causes heightened resistance to a broad variety of therapeutic drugs. Importantly, several drugs that have been evaluated for the treatment of SCI, such as riluzole, are known substrates of Pgp. We therefore examined whether Pgp-mediated pharmacoresistance diminishes delivery of riluzole to the injured spinal cord. Following moderate contusion injury at T10 in male Sprague-Dawley rats, we observed a progressive, spatial spread of increased Pgp expression from 3 days to 10 months post-SCI. Spinal cord uptake of i.p.-delivered riluzole was significantly reduced following SCI in wild type but not Abcb1a-knockout rats, highlighting a critical role for Pgp in mediating drug resistance following SCI. Because inflammation can drive Pgp upregulation, we evaluated the ability of the new generation dual anti-inflammatory drug licofelone to promote spinal cord delivery of riluzole following SCI. We found that licofelone both reduced Pgp expression and enhanced riluzole bioavailability within the lesion site at 72 h post-SCI. This wor…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meanwhile, miR-138-5p downregulation may also limit cytoprotective treatments due to its targeting of MDR1, a channel that confers drug resistance in cancer [96], which becomes upregulated in the damaged spinal cord to limit the effects of Riluzole [97].”
From MicroRNA-138-5p Targets Pro-Apoptotic Factors and Favors Neural Cell Survival: Analysis in the Injured Spinal Cord (2022) · cites this paper as [97]
Citations
Cites
Blood‐spinal cord barrier after spinal cord injury: Relation to revascularization and wound healing
Whetstone, W. D., Hsu, J. C., Eisenberg, M., Werb, Z., & Noble‐Haeusslein, L. J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10759 · Cited by 288
Distribution and time course of protein extravasation in the rat spinal cord after contusive injury
Noble, L. J., & Wrathall, J. R. (1989) · Brain Research · doi:10.1016/0006-8993(89)90542-8 · Cited by 222
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 1×
“Dysfunction of Abcd1 and Abcd2 results in accumulation of VLCFA, causing lipotoxicity-induced, demyelinating inflammation of the brain.(103) Interestingly, it has recently been shown that”
Khan, M., Singh, J., Gilg, A. G., Uto, T., & Singh, I. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002329 · Cited by 49
Research works printed but not linked: 108
- 10.1089/neu.2009.1149 · DOI
- 10.1016/S0959-437X(96)80091-8 · DOI
- 10.2174/1567201043334650 · DOI
- 10.1016/j.tips.2004.06.002 · DOI · Paper page
- Begley D.J., 2005, Efflux Transporters and the Blood–Brain Barrier, 107
- 10.1056/NEJM199511233332103 · DOI
- Marie J.P., 1991, Blood, 78, 586, 10.1182/blood.V78.3.586.586 · DOI
- 10.1097/00001622-200009000-00011 · DOI
- 10.1016/j.neulet.2010.01.078 · DOI
- 10.1038/nn1676 · DOI
- 10.2174/138161211797440186 · DOI
- 10.1016/j.pscychresns.2010.05.002 · DOI
- 10.1016/j.tips.2005.11.009 · DOI
- 10.1124/mol.107.041210 · DOI
- 10.1016/j.pharmthera.2009.10.004 · DOI
- 10.1097/00006123-199905000-00052 · DOI
- 10.1080/10790268.1996.11719436 · DOI
- 10.1097/00006123-199804000-00007 · DOI
- Young W., 1992, J. Neurotrauma, 9, S397
- 10.1097/00002517-199610000-00002 · DOI
- 10.3171/jns.1985.63.5.0704 · DOI
- 10.3171/jns.1992.76.1.0023 · DOI
- 10.1056/NEJM199005173222001 · DOI
- 10.1017/S031716710000754X · DOI
- 10.1227/01.NEU.0000245591.16087.89 · DOI
- 10.3171/jns.1998.89.5.0699 · DOI
- 10.3171/FOC.2008.25.11.E14 · DOI
- 10.1021/js970163u · DOI
- 10.1097/00000542-200001000-00027 · DOI
- 10.1038/sj.sc.3101891 · DOI
- 10.1111/j.1471-4159.2006.03799.x · DOI
- 10.1089/089771503770195867 · DOI
- 10.1523/JNEUROSCI.5275-03.2004 · DOI
- 10.1523/JNEUROSCI.1661-07.2007 · DOI
- 10.1016/j.ejpain.2008.08.001 · DOI
- Milane A., 2007, J. Neurochem., 103, 164, 10.1111/j.1471-4159.2007.04772.x · DOI
- 10.1097/00007632-199510001-00002 · DOI
- 10.3171/spi.2001.94.2.0245 · DOI
- 10.1016/S0079-6123(02)37016-X · DOI
- 10.1016/j.neuroscience.2004.01.019 · DOI
- 10.1089/neu.2010.1539 · DOI
- 10.1016/j.neulet.2009.03.016 · DOI
- 10.3171/jns.1989.71.3.0403 · DOI
- 10.1016/S0750-7658(98)80058-0 · DOI
- 10.1038/sj.sc.3100962 · DOI
- Zhang L., 2003, Acta Pharmacol. Sin., 24, 903
- 10.2165/00023210-200822060-00002 · DOI
- Wiffen P.J., 2011, Cochrane Database Syst. Rev., 2, CD006044
- 10.1016/j.neuropharm.2008.08.032 · DOI
- 10.1016/S0304-3940(02)00423-8 · DOI
- 10.1016/S0893-133X(99)00095-0 · DOI
- 10.1016/j.nbd.2012.03.040 · DOI
- 10.1007/978-1-60761-416-6_15 · DOI
- 10.1111/j.1528-1167.2010.02585.x · DOI
- Liu B., 2009, Cell Biol. Int., 34, 21, 10.1042/CBI20090129 · DOI
- Szczuraszek K., 2009, Oncol. Rep., 22, 1315
- 10.1002/jcb.22239 · DOI
- 10.1016/j.canlet.2011.01.025 · DOI
- 10.1007/s11095-008-9596-1 · DOI
- 10.1002/jnr.21508 · DOI
- 10.1089/neu.1998.15.1005 · DOI
- 10.1007/1-4020-5688-5_1 · DOI
- 10.1146/annurev.biochem.69.1.145 · DOI · Paper page
- Fiorucci S., 2001, Pharmacol., 62, 1433
- 10.1200/JCO.2005.14.209 · DOI
- 10.1158/1078-0432.CCR-04-0945 · DOI
- Mao J.T., 2003, Clin. Cancer Res., 9, 5835
- 10.1016/j.bbagen.2011.02.005 · DOI
- 10.1111/j.1398-9995.1997.tb01039.x · DOI
- 10.1093/carcin/bgi012 · DOI
- 10.1093/rheumatology/keh105 · DOI
- 10.2147/ciia.2007.2.1.73 · DOI
- 10.1007/978-1-60327-389-3_15 · DOI
- 10.1089/neu.2009.0997 · DOI
- 10.1371/journal.pone.0016456 · DOI
- 10.1089/08977150360547099 · DOI
- 10.1089/neu.1995.12.1 · DOI · Paper page
- 10.1016/j.jchromb.2004.11.053 · DOI
- 10.1016/j.jchromb.2004.01.004 · DOI
- Beggs J.L., 1976, Lab. Invest., 34, 428
- 10.1002/(SICI)1096-9861(19961223)376:4<542::AID-CNE4>3.0.CO;2-1 · DOI
- Sinescu C., 2010, J. Med. Life, 3, 254
- 10.1073/pnas.86.2.695 · DOI
- 10.1016/j.neuropharm.2009.09.012 · DOI
- 10.2174/138920111795164020 · DOI
- 10.1212/WNL.47.6_Suppl_4.233S · DOI
- 10.1016/S0304-3940(01)01904-8 · DOI
- 10.1006/exnr.2001.7702 · DOI
- 10.1385/JMN:21:2:173 · DOI
- 10.1124/mol.111.074179 · DOI
- 10.1124/jpet.109.152520 · DOI
- 10.1097/00008571-200210000-00004 · DOI · Paper page
- 10.1097/00008571-200210000-00005 · DOI
- 10.1093/jnen/63.10.1038 · DOI
- 10.1007/s00702-008-0030-y · DOI
- Wijnholds J., 2005, Efflux Transporters and the Blood–Brain Barrier, 137
- 10.1111/j.1528-1167.2006.00939.x · DOI
- 10.2174/1381612043384844 · DOI
- 10.1111/j.1471-4159.2007.05099.x · DOI
- 10.1002/nbm.1343 · DOI · Paper page
- 10.1089/neu.2008.0860 · DOI
- 10.18433/J36C78 · DOI
- 10.2165/00003088-198917020-00004 · DOI
- 10.2174/138920009788498996 · DOI
- 10.1111/j.1471-4159.2006.03993.x · DOI
- 10.1111/j.1572-0241.2004.04133.x · DOI
- 10.1016/j.jneuroim.2005.05.009 · DOI
- 10.1038/sj.bjp.0707577 · DOI
Cited by
Sorted by citations
Maza, R. M., Barreda-Manso, M. A., Reigada, D., Silván, Á., Muñoz-Galdeano, T., Soto, A., del Águila, Á., & Nieto-Díaz, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071559 · Cited by 12
Metadata
- Authors
- Dulin, J. N., Moore, M. L., & Grill, R. J.
- Affiliations
- Department of Integrative Biology and Pharmacology, The University of Texas Medical School at Houston, Houston, Texas.
- Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, Texas.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2013-02
- Volume
- 30
- Issue
- 3
- Pages
- 211-226
- ISSN
- 0897-7151
- 1557-9042
- Cited by
- 24
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review